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Background: Childhood obesity is a serious public health problem associated with the development of several
chronic diseases, such as type 2 diabetes mellitus, dyslipidemia, and hypertension. The elevated prevalence of
obesity is mostly due to inadequate diet and lifestyle, but it is also inﬂuenced by genetic factors.
Objectives: To review recent advances in the ﬁeld of the genetics of obesity. We summarize the list of genes
associated with the rare non-syndromic forms of obesity, and explain their function. Furthermore, we discuss
the technologies that are available for the genetic diagnosis of obesity.
Results: Several studies reported that single gene variants cause Mendelian forms of obesity, determined by
mutations of major effect in single genes. Rare, non-syndromic forms of obesity are a result of loss-of-function
mutations in genes that act on the development and function of the hypothalamus or the leptin-melanocortin
pathway. These variants disrupt enzymes and receptors that play a role in energy homeostasis, resulting in
severe early-onset obesity and endocrine dysfunctions. Different approaches and technologies have been
used to understand the genetic background of obesity. Currently, whole genome and whole exome
sequencing are important diagnostic tools to identify new genes and variants associated with severe obesity,
but other approaches are also useful at individual or population levels, such as linkage analysis, candidate
gene sequencing, chromosomal microarray analysis, and genome-wide association studies.
Conclusions: The understanding of the genetic causes of obesity and the usefulness and limitations of the
genetic diagnostic approaches can contribute to the development of new personalized therapeutic targets
against obesity.
© 2017 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).1. Introduction
Childhood obesity has been recognized as one of the most serious
public health problems of the 21st century,1 and is deﬁned by the
World Health Organization as an abnormal or excessive accumulation
of body fat, sufﬁcient to cause adverse health effects. The body mass
index (BMI, calculated by dividing weight [kilograms] by the height
squared [meters]) is a clinical standard measure of overweight and
obesity and provides an estimate of adiposity in children and adults. In
the measurement of children and adolescents, BMI requires to be
adjusted for both age and gender.1,2unding agencies in the public,
2601, Australia.
gilberto.pazﬁlho@anu.edu.au
P, et al. Genetics of non-sy
s and Its Complications (2017
article under the CC BY-NC-ND liceThe prevalence of childhood obesity has increased at alarming rates,
affecting populations from developed and developing countries.3–5 The
problem is global and tends to increase with the income level of these
countries.6 In 2013, the prevalence of overweight and obesity in
developed countrieswas 23.8% for boys and 22.6% for girls; in developing
countries, it was 12.9% for boys and 13.4% for girls.7 The prevalence of
childhoodobesity in someEuropean countries and theUnited States (US)
has apparently reached a plateau; nevertheless, the prevalence continues
to increase in developing countries.8 Recent data estimate that there are
more than 41 million children worldwide under 5 years of age who are
overweight or obese. Among those overweight children, almost half of
them live in Asia and one quarter in Africa.1,5
Unfortunately, obese children have more than a 50% probability of
carrying their adiposity into adulthood, while nonobese children have
10%.9 Furthermore, childhood obesity is a risk factor for the
development of different comorbidities at a younger age which used
to be considered as diseases seen only in the adult, including type 2
diabetesmellitus, dyslipidemia, hypertension, obstructive sleep apneandromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Rare non-syndromic forms of early-onset obesity.
Gene
ID
Gene name Chromosome
location
Inheritance Protein function Additional features Reference
LEP Leptin 7q32.1 Autosomal
recessive
Stimulates anorexigenic pathway
and inhibits the orexigenic pathway
Low levels of leptin, insulin resistance,
dyslipidemia, susceptibility to infection
diseases and hypogonadotropic
hypogonadism
Paz-Filho et al., 201024;
Montague et al., 199725
LEPR Leptin receptor 1p31.3 Autosomal
recessive
Leptin receptor Immune dysfunctions, hypogonadotropic
hypogonadism, growth hormone
deﬁciency and hypothyroidism
Clement et al., 199826;
Saeed et al., 201427;
Farooqi et al., 2007a28
PCSK1 Proprotein convertase
subtilisin/kexin type
1
5q15 Autosomal
recessive/
dominant
Proteolytic processing of
prohormones and
proneuropeptides
Diabetes insipidus, growth hormone
deﬁciency, malabsorptive diarrhea,
hypogonadism, adrenal insufﬁciency and
hypothyroidism
Farooqi et al., 2007b29
POMC Pro-opiomelanocortin 2p23.3 Autosomal
recessive
Protein precursor of melanocortin
family that transmits leptin effects
to MC4R and regulates the adrenal
growth
Adrenal insufﬁciency and pigmentation
abnormalities
Kühnen et al., 201630
TUB Tubby bipartite
transcription factor
11p15.4 Autosomal
recessive
Modulates anorexigenic
neuropeptides*
Retinal dystrophy Borman et al., 201431
SH2B1 Src homology 2 B
adapter protein 1
16p11.2 * Modulates cell signaling in response
to leptin and other hormones
Insulin resistance, maladaptive behavior,
delayed speech and language
development
Doche et al., 201232;
Rui, 201433
MC4R Melanocortin-4
receptor
18q21.3 Autosomal
co-/
dominant
Transmits the anorexigenic and
orexigenic effects, controlling
satiety and energy expenditure
Hyperinsulinemia, increased linear
growth or isolated obesity phenotype
Doulla et al., 201434;
Farooqi, 200335;
Melchior et al., 201236;
Farooqi, 201537
MRAP2 Melanocortin 2
receptor accessory
proteins 2
6q14.3 Autosomal
dominant
Regulates melanocortin receptors * Asai et al., 201338;
Schonnop et al., 201639
KSR2 Kinase suppressor of
ras 2
12q24 * Involved in cellular fuel oxidation Low heart rate, reduced basal metabolic
rate and insulin resistance
Pearce et al., 201340;
Costanzo-Garvey et al., 200941
SIM1 Single-minded
homolog 1
6q16.3 Autosomal
dominant
Regulates the development and
function of the paraventricular
nucleus
Accelerated linear growth, impaired
concentration, memory deﬁcit, emotional
lability and autistic spectrum behavior
Ramachandrappa, 2013a42;
Holder et al., 200043
BDNF Brain-derived
neurotrophic factor
11p13 Autosomal
dominant
Regulates the development, survival
and differentiation of neurons
Hyperactivity, impaired memory, reduced
nociception, delayed speech and language
development
Gray et al., 200644
NTRK2 Neurotrophic tyrosine
kinase receptor type 2
9q22.1 Autosomal
dominant
BDNF receptor Development delay as well as short-term
memory and nociception impaired
Yeo et al., 200445
LRP2 Low-density
lipoprotein receptor 2
2q31.1 Autosomal
dominant
Binds to the long-form of LEPR and
activates STAT3 signaling
Puberty delay, decelerated linear growth,
hypothyroidism, insulin resistance and
elevated levels of prolactin
Paz-Filho et al., 201446
Notes: *Not yet elucidated.
2 A.C.P. da Fonseca et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxxand steatohepatitis.10 They also have psychosocial and emotional
well-being consequences, since those children are more likely to have
anxiety, depression, poor self-esteem and become victims of bully-
ing.11–13 The increased risk for developing obesity-related disease is
associated with premature death and leads to increased healthcare
utilization and expenditures.14,15 Children with higher BMI utilize
emergency department and outpatient clinic visits more frequently
when compared to underweight/normal weight children.16 In the US,
elevated BMI among children and adolescents costs 14.1 billion
dollars in additional prescription drugs, emergency department and
outpatients clinics visits per year.17 Since obese children and
adolescents have an increased risk of remaining obese as adults, the
Brookings Institution has estimated that obese people have lifetime
societal costs nearly 92,000 dollars greater than normal weight
subjects.18,19
The etiology of childhood obesity is extremely complex, being
clearly inﬂuenced by environmental, behavioral, genetic and ecolog-
ical factors.10,20 Common forms of obesity, which are present in most
cases, are caused by a combination of environmental factors with
many gene variants of minor effect. However, at least ~7% of
non-syndromic early-onset severe obesity (deﬁned by onset before
age 5 and body mass index over three standard deviations above
normal) are monogenic, thereby caused by gene variants of major
effect21–23 (Table 1). In the large universe of obesity, that small
percentage accounts for a substantial number of cases: consideringPlease cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017that between 1.8% to 5.6% of Australian children are severely
obese,47,48 there are between 5000 and 18,000 cases of monogenic
forms of NEOSO (non‐syndromic early-onset severe obesity), which
remain largely undiagnosed.
Population-based approaches such as genome-wide association
studies (GWAS), and other approaches that can be employed at the
individual level, such as sequencing of candidate genes and of the
whole genome or exome, have led to the identiﬁcation of at least 146
genetic variants associated with body mass index (BMI) or
waist-to-hip ratio phenotypes.49 Furthermore, at least twelve gene
variants directly involved in monogenic forms of non-syndromic
human obesity have been identiﬁed,50 including a novel variant in the
low-density lipoprotein receptor 2 (LRP2) gene, identiﬁed by our
group.46
The identiﬁcation of obesity-associated genes has already contrib-
uted to the clariﬁcation of unsuspected biological pathways involved
in the control of energy balance,51 such as the leptin-melanocortin
pathway, and in the neuronal differentiation of the paraventricular
nucleus.52 While there is robust evidence that the heritability of body
weight is prominent, currently only a small fraction of the BMI
variance can be explained by genetic factors.53 Therefore, either most
of the obesity genes remain to be discovered, or their interaction is
unknown.
To broaden our understanding of the importance of gene variants
on non-syndromic excess body weight, several genomic- andndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
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more recently, whole genome sequencing (WGS), whole exome
capture (WEC) and tagged next generation sequencing. This review is
intended to provide comprehensive knowledge to clinicians and
clinical researchers on the genetics of obesity. It will initially present
what is currently known about the genetics of obesity, and will
subsequently discuss the currently available technologies for the
investigation of the genetic causes of excessive adiposity.2. Genetic basis of obesity
Many different hypotheses have been proposed to explain the
origin of the obesity epidemic. It is broadly accepted that the two
major putative contributors are speciﬁc food marketing and con-
sumption habits, and decrease in physical activity. However, there are
others contributors, such as infections, maternal age, sleep debt,
endocrine disruptors (such as industrial chemicals), reduction in
ambient temperature variations, intrauterine and intergenerational
effects, and drug-induced weight gain.54 Despite the importance of all
these contributors, it is known that genetic factors have a key role in
the risk of one becoming obese.
The percentage of obesity that can be attributed to genetics varies
from 6 to 85%.55 Despite high estimates of heritability and decades of
molecular genetic investigation, a very small fraction of genes
associated with obesity have been identiﬁed. Twin studies have
been used to understand the genetic component of obesity.56
Bouchard et al.57 through experiments of overfeeding and regular
exercises, reported that monozygotic twins had more similar changes
of body weight, body composition and energy expenditure when
compared to dizygotic twins. Additionally, adoption studies showed a
strong relationship between the BMI of biological parents and their
adopted children; however no similarity was found with adoptive
parents. These studies suggest that obesity and adiposity are
inheritable factors.582.1. Polygenic obesity
It is well-characterized that the obesity epidemic is not caused by
single gene disorders, but actually has a complex genetic background.
The patient with common obesity has many genetic susceptibility
variants, which have a minor effect on body weight.59 The effect of
genes on the pathogenesis of obesity is more frequently stronger
when combined with other genes and the environment. The
association of these genes with obesity has been evaluated through
several approaches, such as linkage analysis, candidate gene sequenc-
ing and GWAS.
Over the past years, genetic epidemiological studies have
identiﬁed several genes which play important biological roles in
human obesity. Recently, Locke et al.22 carried out GWAS and
Metabochip meta-analysis for BMI. Data was analyzed from 339,224
individuals of 125 different studies. A total of 97 BMI-associated
loci were identiﬁed, of which 56 were novel. Many of these loci were
in/near genes which play a role in different biological processes, for
example, the neuronal development (FAIM2, PTBP2 and ST5),
hypothalamic expression and regulatory function (TMEM18, SCG3
and GRP); limb development (RARB, TFAP2B and LMX1B), lipid
biosynthesis and metabolism (CYP27A1, CYP17A1 and NR1H3), cell
proliferation and survival (PARK2 and OLFM4), and immune system
(IL22RA2, MAN1A1, IFNGR1). Furthermore, some genes have previ-
ously been associated with severe early onset obesity (BDNF, MC4R,
SH2B1, TUB and POMC). These 97 loci account for 2.7% of BMI variation
and it was suggested that their common variants inﬂuence nearly 21%
cases of obesity. Despite this robust study, most of the genetic
variability in human obesity remains unknown.Please cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (20172.2. Mendelian or monogenic forms of non-syndromic obesity
Over the last 15–20 years, it has been characterized that single
gene mutations can cause severe early-onset obesity in humans.60,61
Assessment of such cases has already provided seminal information
on genes involved in critical pathophysiological pathways that can
lead to obesity. These genes encode enzymes and receptors that have
a physiologic role in the development of the hypothalamus and the
leptin-melanocortin system.
2.2.1. The hypothalamic development and the appetite control
The hypothalamus is the region of the brain involved in the
regulation of the body's temperature, fertility, thirst and appetite.62
The role of the hypothalamus in severe obesity has been postulated
since the early twentieth century. Initially, chemical and electrical
experiments that damaged the hypothalamus of cats and mice were
correlated with an increase or loss of weight, depending on the size
and location of the lesion. These experiments suggested the existence
of a speciﬁc circuit in the hypothalamus that promoted or suppressed
food intake.63,64 In humans, patients with tumors in the hypothalamic
region are obese, suggesting an involvement of the hypothalamus in
the regulation of body weight.65 Nowadays, it is known that the
hypothalamus acts to maintain energy homeostasis, by receiving
information about the body's nutritional status and energy stores,
through neural and hormonal signals.61,66
The neuronal differentiation of the hypothalamus is controlled by
several proteins, including brain-derived neurotrophic factor (BDNF),
transcription factor single-minded 1 (SIM1) and the tyrosine kinase
receptor (TRKB).62,67 Interestingly, pathogenic mutations which
disrupt these protein functions can lead to severe onset-obesity in
humans.42,44,45
The development of obesity results from imbalance between
energy intake and expenditure over a prolonged period.68 One of the
most important pathways responsible for controlling food intake and
body weight is the leptin-melanocortin system, located in the
hypothalamus. This system is an important pathway to energy
balance that integrates information from energy stores and nutri-
tional status in peripheral organs with a neural circuit.66
This pathway is activated when leptin, produced by adipocytes,
crosses the blood-brain barrier and binds to its receptors, localized in
two different groups of neurons in the arcuate nucleus of the
hypothalamus. Both groups of neurons act on the regulation of food
ingestion and energy expenditure, which are important for energy
homeostasis. One of these groups expresses neuropeptide Y (NPY)
and agouti-related protein (AgRP) that stimulates food intake
(orexigenic pathway), while the other expresses proopiomelanocor-
tin (POMC) and cocaine and amphetamine-regulated transcript
(CART) which inhibits food consumption (anorexigenic
pathway).69,70
The brain can control energy homeostasis since it receives
information about the body's nutritional status and energy stores by
peripheral hormones. When the body has food restrictions, is fasting
and/or has a decreased energy stock, the stomach secretes ghrelin that
binds to the ghrelin receptor, localized in the orexigenic neurons,
increasing the production of NPY and AgRP. The orexigenic neurons
project to the paraventricular nucleus (PVN) of the hypothalamus and
their neuropeptides act as antagonists of melanocortin receptors,
which stimulate food intake and decrease the basal energy expendi-
ture. However, when the body has adiposity and/ or energy
replacement, the white adipose tissue secretes leptin that binds to
leptin receptor (LEPR), localized in the orexigenic neurons, suppress-
ing this pathway. Furthermore, leptin binds to its receptor on
anorexigenic neurons, increasing the production of POMC and CART.
The POMC hormone is a protein precursor which is processed and
cleaved into α melanocyte stimulating hormone (α-MSH) by
proprotein convertase 1/3 (PC1/3) and binds to the melanocortin-4ndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
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Fig. 1. Hypothalamic mechanisms of appetite control. Hypothalamic leptin-melanocortin pathway regulated by leptin and ghrelin. Leptin activates anorexigenic neurons
proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) which inhibit food consumption, and inhibits neuropeptide Y (NPY) and agouti-related
protein (AgRP), stimulating food intake (orexigenic pathway). Ghrelin is the only orexigenic peptide, secreted by the stomach.
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Activation of MC4R by α-MSH and CART increases a satiety signal,
suppressing appetite and increasing basal energy expenditure.71–73
Interestingly, mutations in genes involved the leptin-melanocortin
pathway demonstrate the critical role of energy balance and have
been associated with development of severe early-onset obesi-
ty.50,74,75 Fig. 1 summarizes the hypothalamic mechanisms involved
in appetite control.
2.2.2. Recessive forms of non-syndromic monogenic obesity
The ﬁrst evidence of monogenic obesity was found in rodents in
the early 1950s. It was reported that ob/ob mutant mice have four
times higher weight than normal animals.76 Through further studies,
Coleman77 discovered that ob/ob mice have a deﬁciency of the
signaling pathway from adipose tissue, which regulates food intake
and metabolism. After positional cloning and sequencing, the leptin
gene (lep) was identiﬁed and characterized.78 In humans, pathogenic
mutations in the LEP gene are associated with low levels of leptin,
hyperphagia and severe early-onset obesity.25,79,80
For over 15 years, researchers have been evaluating phenotypic
ﬁndings and the effects of leptin replacement in less than a dozen of
the ≤40 leptin-deﬁcient individuals identiﬁed in the world. Our group
has been following one child and three adults from a consanguineous
extended Turkish family (summarized in24,81,82). These individuals
have a Mendelian recessive mutation in the LEP gene, consisting of a
C → T substitution in codon 105 of this gene, resulting in an
Arg → Trp replacement in the mature protein. Three of them are the
only leptin-deﬁcient patients identiﬁed during adulthood in theworld
to date. Physiological doses of recombinant methionyl human leptin
(r-metHuLeptin, metreleptin, Aegerion Pharmaceuticals, Inc., USA,
0.02–0.04 mg/kg/day) were started at ages 5 (boy), 27 (man), 30 and
40 (women), leading to signiﬁcant improvements in body weight,
endocrine function and behavior.83 Leptin replacement was lifesav-
ing, as eight members of this family with NEOSO, whom we presume
to have been leptin-deﬁcient, died of immune deﬁcits in childhood.
The study of recessive forms of monogenic extreme obesity
has been useful in delineating the role of genes from the leptin-Please cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017melanocortin pathway. However, these recessive forms of obesity due
to functional mutations in the LEP are very rare, and mostly identiﬁed
in families with high levels of consanguinity. To date, ≤40 individuals
have been found to be homozygous for each of these mutations.
However, a systematic effort to sequence LEP in 73 individuals with
NEOSO revealed that 22% were homozygous for LEP mutations,
resulting in impaired leptin signaling.80 This study showed that a
systematic genetic examination of early-onset severe obesity, even by
focusing on a few genes, could reveal a meaningful percentage of
monogenic cases of obesity. It is important to note that, although most
patients with the leptin-deﬁcient phenotype have low or undetectable
serum leptin levels, one patient had detectable, but biologically inactive
serum leptin.84
Besides LEP, homozygous loss of function mutation of its receptor
LEPR is associated with severe hyperphagia and early-onset extreme
obesity in humans. Initially, homozygous mutations in LEPR were
identiﬁed in patients characterized by hyperphagia, early-onset
morbid obesity, failure of pubertal development and impairment in
secretion of growth hormone and thyrotropin. These patients had a
base substitution in the splice donor site of exon 16, which results
from skipping this exon and generates a truncated receptor that lacks
both the transmembrane and intracellular domains.26 Afterwards,
Farooqi et al.28 reported eight severely obese subjects that had
nonsense or missense LEPR mutations. The nonsense mutations were
predicted to result in a lack of all receptor isoforms, and the missense
variants impaired receptor signaling. Recently, two novel frameshift
mutations were identiﬁed in severely obese children by whole-exome
sequencing. Both mutations generate an abnormal protein that lacks
the leptin binding receptor domain (CRH2), affecting all isoforms.85
On the whole, congenital deﬁciency of LEP or LEPR disrupts leptin
signaling and is characterized by similar clinical data.28
POMC is a complex propeptide expressed in the hypothalamus,
pituitary gland and brainstem that is activated by tissue-speciﬁc
post-translational processing.62 POMC generates a family of melano-
cortin peptides, for example the adrenocorticotropic hormone (ACTH)
and α–, β-, and γ-melanocyte-stimulating hormones (MSH). These
peptides have an important role on skin pigmentation, the control ofndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
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inactivate the POMC gene have been reported in children, leading to
severe early-onset obesity, adrenal insufﬁciency and pigmentation
abnormalities.87,88 Krude et al.88 reported the ﬁrst human description
of congenital deﬁciency of POMC. They identiﬁed two unrelated
children who had severe childhood obesity, adrenal hypoplasia, red
hair and pale skin. One patient had a compound heterozygous variant
for two nonsense mutations and the second had a homozygous
variant for the new initiation site of translation, localized in the
5-untranslated region. Although POMC mutations could result in a
pigmentation abnormality, this characteristic was absent in different
case reports.24,46,82,89 For example, Mendiratta et al.90 identiﬁed an
18-month-old female with congenital adrenal insufﬁciency caused by
a homozygous C → A substitution in codon 231 of POMC gene, which
was predicted to result in a premature stop codon. The clinical
phenotype of the patient was similar to previous reports, however the
child had dark colored hair and dark roots. More recently, another
interesting variation in the classical phenotype of POMC deﬁciency
was described by Samuels et al.91 They reported a 4-year-old girl and
a 4-month-old boy who had high circulation levels of ACTH caused by
variants that generate non-functional peptides, but immunologically
detectable.
In the last 20 years, researchers have identiﬁed variants in POMC
that cause congenital deﬁciency; however, only the adrenal insufﬁ-
ciency phenotype is treatable, by using hydrocortisone.92 This year,
Kühnen et al.30 reported two obese POMC-deﬁcient patients that were
treated with daily subcutaneous synthetic melanocortin (setmelano-
tide), resulting in body fat loss, decreased appetite and darkening of the
skin and hair. Setmelanotide, also known as RM-493, binds to theMC4R
and activates the anorexigenic pathway, substituting the lack of MSH in
those patients. Although this study shows a limitation in the number of
patients, setmelanotide may offer a potential treatment for POMC
deﬁciency in the future. Furthermore, they speculated that synthetic
melanocortin might be useful for treating LEPR and PCSK1 deﬁciency
patients.
In addition, null mutations in proprotein convertase subtilisin/
kexin type 1 gene (PCSK1) cause a rare non-syndromic form of
obesity.93 PCSK1 encodes the PC1/3 that is expressed in neural and
endocrine tissues.94 In the brain, PC1/3 is highly expressed in the
hypothalamus where it acts on cleavage processing of POMC to
α-MSH.66,95 Several cases of PC1/3 deﬁciency were reported with
hyperphagia, central diabetes insipidus, severe malabsorptive diar-
rhea and other endocrines dysfunctions. This deﬁciency could be
explained by mutations that affect protein maturation and generate
impairment in the catalytic activity, resulting in a truncated protein or
lack of protein.29,93,96–98 Although PC1/3 deﬁciency is described as an
autosomal recessive disorder, the severe obesity phenotype has been
associated with loss of one wild-allele. Philippe et al.99 identiﬁed a
heterozygous non-synonymous mutation that is co-segregated with
obesity in three generations of a French family. This variant, located in
the second exon of PCSK1, affects both mutant and wild-type proteins
activity in vitro. This autosomal dominant inheritance of obesity may
be explained by the truncated propeptide which also interferes with
the function of the wild-type protein.
Recently, Borman et al.31 identiﬁed a homozygous frameshift
mutation in tubby bipartite transcription factor gene (TUB) which was
associated with early-onset obesity as well as retinal dystrophy in
humans. This variant is found in a conserved region of TUB family
resulting in a truncated protein, which has an incorrect localization in
the cell. Moreover, loss of function mutation in the Tub gene also
induces obesity in mice.100 The role of TUB in energy balance has not
been totally elucidated; however it is expressed in different regions of
the hypothalamus, including the arcuate nuclei and paraventricular
nuclei. Additionally, experimental data suggests that the TUB protein
acts onmodulating anorexigenic neuropeptides, and low levels of TUB
expression result in increased food intake and adiposity.101Please cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (20172.2.3. Dominant forms of non-syndromic monogenic obesity
The progress in understanding the obesity background is mostly
due to the identiﬁcation of rare genetic forms. Although several gene
variants have been identiﬁed to cause recessive forms of obesity,
heterozygosity for deleterious mutations in BDNF, NTRK2, SIM1,MC4R,
SH2B1, MRAP2 and LRP2 have also been associated with severe
early-onset obesity.
BDNF, NTRK2 and SIM1 are responsible for coding important
proteins to the development of the hypothalamus.62 BDNF and its
receptor TrkB (encoded by NTRK2) are involved in the proliferation,
survival, and differentiation of neurons in the central nervous
system, especially the hypothalamic neurons.102 SIM1 is a transcrip-
tion factor that plays a major role in the development and function of
the paraventricular nucleus, a critical region for food intake
regulation.43 In humans, pathogenic mutations in those genes are
associated with hyperphagia and severe obesity phenotype. A de
novo heterozygous missense mutation (Y722C) in NTRK2 was found
in an eight-year-old male patient with severe obesity, nociception,
impaired short-term memory and learning.45 Functional analysis
demonstrated that Y722C leads to TrkB dysfunction.103 Furthermore,
a de novo paracentric inversion in chromosome 11 (46, XX, inv (11)
(p13p15.3)), which disrupts one copy of the BDNF gene, was
identiﬁed in a child with severe obesity, impaired cognitive function
and hyperactivity.44
Obesity also has been associated with SIM1 haploinsufﬁciency in
humans. Initially, a female patient was identiﬁed with severe
early-onset obesity that had a balanced translocation (46, XX,
t(1;6)(p22.1;q16.2)), leading a disruption of SIM1 in one allele.104
In addition, rare missense mutations in SIM1 have been associated
with obesity.105,106 Recently, the coding region of SIM1 was
sequenced in 2100 severe early-onset obesity probands and in 1680
controls, identifying 13 heterozygous variants in 28 patients, in which
nine of these mutations would reduce the activity of SIM1 in vitro.
Among these patients with pathogenic variants, 11 individuals had
evidence of cognitive deﬁcit including impaired concentration,
emotional lability and memory deﬁcit, in addition to severe
early-onset obesity.105 A similar analysis was performed in 561
overweight/obese subjects, and identiﬁed four heterozygous rare
nonsynonymous variants in SIM1 gene, in which two of these
mutations caused impairment in the SIM1 function.106 Therefore,
BDNF, NTRK2 and SIM1 haploinsufﬁciency are associated with severe
early-onset obesity as well as cognitive impairment in humans.
MC4R is the receptor for α–MSH and, as such, plays a key role in
energy homeostasis, food intake and body weight, since it regulates
satiety.107 Consistent with this role, loss of function MC4R mutations
are associated with increased appetite that leads to severe early-onset
obesity in humans.35,108 Nowadays, more than 150 variants are
known, and the prevalence of deleterious MC4R variants ranges from
0.5% up to 5% in obese children.60,109,110MC4Rmutations are the most
common genetic cause of monogenic obesity and also contribute to
polygenic forms.111,112 The rare cases ofMC4R deﬁciency are inherited
in a co-dominant form.37,113 Several cases of MC4R deﬁciency
described patients with early-onset obesity, hyperphagia, severe
hyperinsulinemia and increased linear growth, although the endo-
crine and anthropometric phenotypes were not conﬁrmed in other
reports.34–36 Recently, theMC4R gene was sequenced in a large cohort
of obese children and adolescents from Germany. MC4R mutations
were detected in 22 probands, in which fourteen patients had variants
causing loss of function or impaired the receptor signaling.114 Since
pharmacological drugs are being developed to treat MC4R-deﬁcient
patients, it is extremely important to identify pathogenic
mutations.115,116
It has been recognized that accessory proteins can regulate
melanocortin receptors such as MC4R.38,42 Melanocortin 2 receptor
accessory protein 2 (MRAP2) is expressed in regions involved in
energy balance, such as the hypothalamus and brainstem.ndromic childhood obesity and the use of high-throughput DNA
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mRNAs is coexpressed in the brain, suggesting an involvement of
MRAP2 in the energy homeostasis.38,117 To explore if MRAP2
mutations have an important role in human obesity, the coding
region of this gene was screened in 483 children and adolescents
with extreme obesity and 630 individuals with normal weight.
Three missense mutations were detected among obese subjects, all
in heterozygosis. In vitro functional analyses revealed that one of
nonsynonymous variant (p.Gln174Arg) causes a partial MC4R loss
of function.39 Additionally, four heterozygous mutations were
identiﬁed in patients with severe early-onset obesity, suggesting
that MRAP2 variants may contribute to rare cases of monogenic
obesity.38
Src homology 2 B adapter protein 1 (SH2B1) encodes a cytoplas-
matic adaptor protein, which modulates leptin-melanocortin signal-
ing.33 Heterozygous frameshift and missense variants in SH2B1 were
associated with obesity, insulin resistance and behavioral abnormal-
ities, including a tendency for social isolation and aggressive
behavior.32,118 Furthermore, severe early-onset obesity and severe
insulin resistance phenotypes were reported in a patient with a
220-kb segment deletion of chromosome 16p11.2, where several
genes are located, including SH2B1.119 Several SH2B1 variants in
heterozygosis have been reported and one in homozygosis. All
variants except one co-segregated with obesity in families in a
classical Mendelian manner.118
Additionally, kinase suppressor of ras 2 (KSR2), which acts as a
scaffolding protein, was previously associated with obesity.40 KRS2
plays a role in energy homeostasis, insulin sensitivity and cellular fuel
oxidation. Early studies demonstrated that deletion of Ksr2 in mice is
associated with obesity and insulin resistance.41,120 Furthermore,
KSR2 is located in a chromosome region linked to obesity and type 2
diabetes.121,122 To examine whether KRS2 is involved in human
obesity, the coding region and intron/exon junctions of KSR2 were
screened in 2101 patients with severe early-onset obesity and 1536
normal weight controls. A total of 31 different rare frameshift,
nonsense or missense mutations were identiﬁed, 27 in severely obese
subjects and 7 in controls. Most of the variants impaired the KSR2
function and were found in a heterozygous manner. Curiously, some
loss of functionmutations in KSR2were not co-segregated with severe
obesity, suggesting that other factors may modulate the phenotype
caused by some variants.40
More recently, we added LRP2 to the list of genes associated
with dominant monogenic obesity.46 By submitting three Brazilian
patient-family trios to WEC and parallel sequencing studies, we
identiﬁed one male teenager with compound heterozygous
mutations in the LRP2 gene (conﬁrmed by Sanger sequencing).
LRP2 binds to the long-form leptin receptor (LepRb), forming a
complex that is co-localized and subjected to endocytosis in the
hypothalamic neurons. Subsequently, the endocytosis of this
co-localized complex leads to the activation of signal transducer
and activator of transcription 3 (STAT3) signaling in hypothalamic
neurons. As a consequence, food intake and body weight are
decreased. In the absence of functional LRP2, STAT3 signaling is
decreased. Therefore, hunger is stimulated and satiety de-
creased,123 leading to obesity.
3. Approaches for the genetic diagnosis of obesity
3.1. Linkage analysis
Linkage analysis is the most used method for the genetic mapping
of Mendelian traits with familial aggregation. This genetic approach
accounts for the transmission pattern from parents to offsprings, as
well as the respective affection status of the family members, along
with their allele frequencies for variants/loci under investigation. This
quantiﬁcation process also considers instances of recombinationPlease cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017among loci being tested. All of this information is used to generate
a likelihood ratio under the alternate hypothesis (i.e. evidence of
linkage or co-segregation between variants and the disease). This is
conditional on the premise that the recombination fraction is b0.5,
and rejection of the null hypothesis (no linkage/co-segregation).
Therefore, two linked loci yield a recombination frequency that is
less than 0.5 according to the laws of segregation and independent
assortment hypotheses, represented by a logarithm of the odds
(LOD) score. It is used to identify loci which co-segregate with a
disease or speciﬁc phenotype within related individuals. It is
noteworthy that the discovery of the leptin gene by positional
cloning used the concept of linkage in its methodological
approach.78
The availability of nuclear families (including parents and
offspring) or extended families displaying the obesity phenotype
would constitute a suitable paradigm to perform linkage analyses.
It is also noteworthy to remark, that in this type of approach,
genetic homogeneity is maximised, which also renders these
analyses very powerful. This is the case even for small numbers of
families, provided that cohorts are selected from genetically
homogeneous populations. On the other hand, association studies
are only able to detect allele-frequency differences between cases
and controls of lower phenotypic effect and that requires extremely
large sample sizes. Thus, the fact that the LOD score calculation
accounts for many of these factors, and not just allele frequency
differences between cases and controls, it renders a much more
powerful outcome than GWAS and/or other association analyses.
This would be especially the case if patients are carrying extreme
phenotypic forms of the disease, when trying to identify rare
variants of major effect. GWAS, on the other hand often relies on
common-disease common-variant hypothesis, so at best they can
only detect variants of small effect. In order to detect rare-variants
of major effect in association studies, very large sample sizes are
needed. The latter can be addressed with algorithms that use
rare-variant collapsing/grouping strategies at the gene level (see
below), but they do not have the advantages of mathematically
incorporating information of familial segregation patterns, as
mentioned earlier for linkage analyses.
Finally, new linkage algorithms have emerged that are capable of
identifying de novo mutations as candidate disease variants. Thus,
with all of these advantages, there have been new strategies
developed to combine the strengths of linkage and association
analyses.124 While this has the advantages of evaluating familial
co-segregation, it will also ensure that the variants under investiga-
tion are not overrepresented in sets of unaffected controls, whichmay
be unrelated to the families tested for linkage. In consideration of all of
this, one has to state then, that linkage analyses are at least as
powerful as association studies.3.2. Candidate gene sequencing
This approach aims to study genetic markers in candidate genes
for a speciﬁc characteristic. These genes are previously selected by
evidence of involvement in relevant pathways to the phenotype
studied as well as earlier results that showed a possible association
of the gene and the disease.125 The candidate variants of this gene
are then submitted to Sanger sequencing for validation, and their
sequences are compared against the reference human genome.
Sanger sequencing has been the gold-standard for validating
genomic ﬁndings for over 2 decades. In well-selected cases,
sequencing can lead to a genetic diagnosis in up to 46% of
patients.126 Currently, next generation sequencing is a very
cost-effective ﬁrst line approach, even when there is high suspicion
for a speciﬁc gene. Sanger sequencing is then employed to validate
the next generation sequencing ﬁndings.ndromic childhood obesity and the use of high-throughput DNA
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Different studies are focused on identifying copy number varia-
tions (duplications or deletions or chromosomal segments; CNV) to
increase the knowledge on obesity susceptibility. Previous studies
reported that individuals with severe early-onset obesity have an
enrichment of CNVs, suggesting that variationmay represent a risk for
this disease.127 Considering that fact, the chromosomal microarray
analysis has been a useful tool to search for CNVs in the genome.128
Chromosomal microarray is particularly useful for identifying
microdeletions, microduplications, and most of abnormalities regard-
ing chromosomal number. It can also, although with less power,
identify most of the non-balanced rearrangements, imprinting,
triploidy, and punctual mutations. However, it cannot identify larger
deletions and mutations, such as fragile X syndrome, and balanced
rearrangements, such as inversions and balanced translocations.
3.4. GWAS
The new age of technology has been allowing the identiﬁcation of
common variants associated with complex multigenic disorders. In
GWAS, a huge number of DNA markers across the genome is scanned,
and through statistical analysis, it is possible to identify the loci
associated with disease or speciﬁc phenotype.60 Until now, GWA
methodologies have been found in 119 common gene variants as
being linked to obesity susceptibility or related traits.50 The fat mass
and obesity-associated gene (FTO) was considered the ﬁrst locus
found in GWAS of obesity. Furthermore, this result was replicated in
different studies including cohorts of European and African descent.
These researchers identiﬁed a cluster of common variants in the ﬁrst
intron of FTO that is associated with increased BMI. Moreover, these
common polymorphisms were associated with body weight and body
fat distribution.129–131
More recently, a GWAS meta-analysis study identiﬁed 97 loci
linked to obesity explaining 2.7% of BMI variation. Although GWAS
have been an efﬁcient and robust method to identify regions that are
predisposed to obesity, the results are not strong enough to explain
the estimated heritability of this disease.22 Furthermore, GWAS are a
useful approach for identifying common variants and loci associated
with polygenic obesity at a population level, but not applicable in the
diagnosis of Mendelian form at the individual level. Thus, more
molecular studies and newmethodologies are required to understand
the genetics of obesity.
3.5. Next generation sequencing
The comprehension of the genetic background of obesity has
required different molecular strategies, since it is not completely
elucidated yet. Recently, a more precise and fast screening approach
has been developed and applied successfully in the diagnosis of
monogenic forms of obesity.59,132 Next generation sequencing
(whole-genome and whole-exome) allows the identiﬁcation of
mutations that might lead to personalized medicine resulting in a
better life for the patient.99 One of the most common examples is the
severely obese patients carrying loss of function mutations in the LEP
gene, who can be treated with recombinant leptin.81,133
Next generation sequencing (NGS), particularly WEC, has been
used in the clinics for the diagnosis of diseases such as neurodevelop-
mental and autoimmune disorders.134,135 It can provide a diagnosis in
22%–46% of cases, and is indicated by the American College of Medical
Genetics and Genomics (ACMG) in case the phenotype and family
history strongly suggest an unspeciﬁc genetic disease, when there is
signiﬁcant genetic heterogeneity, and when other speciﬁc tests are
negative.136 Sequencing of trios (both biological parents, besides the
proband) leads to higher chance of discovery of signiﬁcant mutations
(30%, vs 23% when just the proband is sequenced). Besides, itPlease cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017improves the detection of de novo mutations and of compound
heterozygotes.137 When siblings are sequenced, the chance of
discovery of recessive mutations is increased; singleton sequencing
leads to higher diagnostic rates in children (23%, vs. 18% in adults).138
Currently, whole-exome sequencing has become more commonly
used to identify variants, since it is more affordable than the
whole-genome sequencing, and it covers 95% of the protein-coding
genome, comprised by ~20,000 genes. The application of
whole-exome sequencing in the obesity ﬁeld has recently begun,
but it already helped to identify novel genes associated with severe
early-onset obesity not detected from previous approaches (KSR2,
SH2B1 and LRP2).32,40,46,118 Additionally, Saeed et al.80 analyzed 73
children with severe obesity from Pakistan and identiﬁed loss of
function homozygous variants in LEP, LEPR and MC4R genes,
explaining 30% of cases. The same group sequenced the coding region
of 26 genes linked to obesity including LEP, LEPR,MC4R, NTRK2, PSCK1,
POMC and SIM1. They found two probands with severe early-onset
obesity and high leptin levels which have two novel LEPRmutations in
homozigosity.27 Therefore, both whole-exome and whole-genome
sequencing are important tools for genetic diagnosis of rare obesity
forms.
One of the main challenges of WEC and WGS is the bioinformatics
analysis of the massive amount of data that is generated. The
employed analysis framework greatly varies among bioinformati-
cians, which can affect the ultimate result. Brieﬂy, the resulting data is
submitted for ﬁltering using a database (usually, dbSNP), to remove
common polymorphisms. Subsequently, variants are annotated by
bioinformatics software, such as SIFT, PolyPhen, CONDEL, to highlight
variants that affect coded proteins. Pathway analysis is performed, to
assess the role of the variant in physiological pathways, and functional
validation is conducted.
Technical limitations of WEC include the fact that 5% of the exome
is not covered, and some mutations may be missed. Furthermore,
WEC only covers protein coding regions which is less than 2% of the
genome. Also, some areas composed by CG repeats are difﬁcult to
sequence, small insertions/deletions (indels) provide inaccurate data,
and extended genes and pseudogenes are difﬁcult to map. Extended
structural variations are better detected by WGS, and CNVs are better
assessed by chromosomal microarray. In NGS, often several poten-
tially pathogenic variants are identiﬁed, which clinical signiﬁcance is
uncertain – those are called “variants of uncertain signiﬁcance”. It is
up to the clinical geneticist to assess whether variants identiﬁed by
NGS are associated with the phenotype.
Of clinical relevance in the USA, the ACMG determines that
laboratories conducting NGS must analyze and report mutations in 56
genes that have been associated with 24Mendelian disorders. Besides
reporting mutations that are known to cause the disease that led the
patient to seek genetic diagnosis, laboratories may also report
incidental or secondary results, that are not related to the main
reason of genetic testing. To minimize distress to the patients and
their families, it is recommended that patients attend pre-test
counseling, when they are informed about the possibility of incidental
ﬁndings, and choose whether they want to be informed or not
(“opt-out”).
Negative results from the NGS do not exclude disease. Since those
approaches and tools are in constant evolution, data can be
reanalyzed after 6–12 months, when new genes, bioinformatics
algorithms, and case reports are made available. If the WEC provides
negative results, another alternative is to perform WGS, which more
uniformly covers coding regions not well covered by WEC, and is able
to detect structural rearrangements and CNVs (unlike WEC).139
3.5.1. RVAT (rare-variant association tests)
While analyses from GWAS have successfully identiﬁed disease-
causing variants in the past, they rely on the common disease,
common variant hypothesis. Therefore, such analyses are not suitablendromic childhood obesity and the use of high-throughput DNA
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Table 2
Statistical quantiﬁcations of network analysis for monogenic obesity-related genes as implemented in Metacore algorithms.
Gene Process ontology Network nodes Ontology P-value Network z-score Network P-value
LRP2 LEP
LEPR
POMC
Regulation of lipid metabolism Leptin binding to leptin receptor (activation).
Receptor binds and activates STAT5B
Casein kinase II phosphorylate LRP2 (activation),
LRP2 inhibits cytochrome c by binding.
5.524e^−4 143.67 8.48e^−70
LRP2 LEP
LEPR
POMC
Response to nutrient levels Leptin binding to leptin receptor (activation).
Receptor binds and activates STAT5B
Casein kinase II phosphorylate LRP2 (activation),
LRP2 inhibits cytochrome c by binding.
1.011e^−12 143.67 8.48e^−70
LRP2 LEP
LEPR
POMC
Regulation of carbohydrate
metabolism
Leptin binding to leptin receptor (activation).
Casein kinase II phosphorylate LRP2 (activation),
LRP2 inhibits cytochrome c by binding.
1.106e^−3 143.67 8.48e^−70
LRP2
LEP
LEPR
POMC
Regulation of protein
metabolic process
Leptin binding to leptin receptor (activation).
Receptor binds and activates STAT5B
Casein kinase II phosphorylate LRP2 (activation),
LRP2 inhibits cytochrome c by binding.
2.330e^−30 143.67 8.48e^−70
LRP2 Negative regulation of
proteolysis
Casein kinase II phosphorylate LRP2 (activation),
LRP2 inhibits cytochrome c by binding.
1.725e^−7 143.67 8.48e^−70
P-values for process ontologies from the GeneGo database are given for the corresponding nodes in the network. Degree of enrichment for constructed network is calculated by
z-score, based on number of genes from the input list. Signiﬁcance of enrichment is given in Network P-value.
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especially given the hypothesis which states that disease causing
alleles of large effect are likely to be of low frequency. Hence, in recent
years, novel methods to perform rare-variant association tests
(RVATs) have been developed. The most notable of these is the
KBAC or Kernel Based Adaptive Cluster. Each rare variant within a
particular gene is collapsed into multi-site genotypes. Thus, in brief,
multi-site genotype frequency differences between cases and controls
are calculated, as opposed to quantifying single variants only. This
gene-based association test ensures that rare variants of potentially
major effect are not completely discounted due to small individual
effect size.140
4. Network analysis of genes underpinning rare non-syndromic
childhood forms of obesity
In order to better understand the potential mechanistic role of
LPR2 in morbid obesity, as previously described by our group, we ran
analyses of pathways and network building algorithms from the
Metacore GeneGo Software Suite from Thomson Reuters (version
6.29, build 68,613). Further details of the statistical analysis
implemented in the various network-building algorithms can be
found in supplementary materials and elsewhere.135 These proce-
dures allowed for the heuristic integration of maps and networks and
corresponding ontologies for obesity related processes in order to
quantitatively and qualitatively evaluate the biological role of LRP2 in
the context of all the other obesity-related genes described in Table 1.
The results of the aforementioned analyses are described in Fig. 1
and Table 2. As shown in Fig. 1, leptin binds to its receptor (LEPR), and
subsequently STAT3, STAT5B and JAK2 bind to the intracellular
domain of LEPR. Thereafter, JAK2 phosphorylates STAT3, STAT5B and
ERK1/2, leading to three different pathways within this network.
Phosphorylated STAT3 translocates into the nucleus to transcription-
ally regulate (TR) c-Myc and POMC. The latter is then exported to the
extracellular domain. Phosphorylated STAT5B also translocates to the
nucleus to transcriptionally regulate Bcl-6, which in turn transcrip-
tionally regulates casein kinase-2 (CK2) (where it is not known
whether this has an activating or inhibitory effect). Thereafter, CK2
phosphorylates LRP2, which in turns binds to cytochrome-C (CYT-C)
with an inhibitory effect. Phosphorylated ERK1/2 can phosphorylate
c-Jun, which within the nucleus can transcriptionally regulate thePlease cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017expression of CYT-C that subsequently translocates to the membrane.
The pathway connecting ERK1/2 to CYT-C has been described, but was
not signiﬁcant with the “response to nutrient levels processes” (hence
a question mark is shown in Fig. 1 linking these nodes). However, the
fact that the proteins encoded by LRP2 as well as the LEPR and its
ligand are simultaneously linked (shown by these algorithms) to
regulation of lipid storage and carbohydrate metabolism, means that
they may have some potential pathway and network interactions in
the biological processes and mechanisms of morbid obesity (Fig. 2).
Themain processes in which LRP2was found associated to a subset
of the genes causing monogenic forms of obesity are nutrient sensing
processes and carbohydrate and lipid metabolism (Table 2). In Table
2, it is shown that there is evidence for the relatedness of LRP2 with
monogenic genes causing extreme forms of morbid obesity as
quantiﬁed by the following statistical analyses described below.
Firstly, the z-score of 143.67 of the constructed network yielded a
P-value of 8.48 × 10−70. Thus, this indicates that there is a signiﬁcant
degree of enrichment of the network with genes from the candidate
input list. Hence, this network is potentially a highly accurate
representation of the potential biological links and interactions of a
subset of these candidate genes out of all those analyzed. The P-values
for these three particular processes are 1.011 × 10−12, 1.106 × 10−3
and 5.524 × 10−4 respectively (Table 2). Therefore, the probability
that these nodes within the network (including proteins encoded by
LRP2 as well as LEP, LEPR and POMC) are associated with these
processes simply due to chance (according to the hypergeometric
distribution calculation under the null hypothesis) is considerably
low. Thus, based on this evidence, one can postulate that amutation in
the LRP2 gene can alter those mentioned processes and pathways,
which may have substantial implications in morbid obesity.5. Genetic diagnosis applied for patient suspected of NEOSO
Monogenic obesity syndromes and nonsyndromes are rare and
mainly result in severe early onset-obesity. These disorders may occur
due to chromosomal abnormalities and/or highly penetrant genetic
variants in critical genes for regulation of energy intake and
expenditure.141 Recently, a clinical practice guideline was published
suggesting how to proceed with patients suspected of Mendelian
forms of obesity.142 Specialists have suggested that all assessment ofndromic childhood obesity and the use of high-throughput DNA
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Fig. 2. Diagrammatic representation of network analyses for monogenic morbid obesity-related genes. This diagram shows the involvement of a subset of the input gene list from
Table 1 (red font) in a network comprising different compartments: extracellular, membrane, cytoplasm and nucleus. Solid arrows depict activation and broken arrows show
inhibition. Thin solid arrows depict unknown effect (i.e. it is uncertain whether there is inhibition or activation). The question marks “?” depict interactions that were described in
other processes but that did not show relatedness to the processes mentioned in Table 2 as they are seemingly not thoroughly annotated within the Metacore GeneGo database.
However, they are part of the same network and may have relevant interactions as shown in this ﬁgure. The abbreviations “TR”, “B” and “P” indicate transcriptional regulation,
binding and phosphorylation, respectively.
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help to guide the disorder diagnosis.
Based on the practice guideline, physical examination and medical
history about the patient is required to establish the age of obesity
onset, presence of hyperphagia, developmental delay and/or dysmor-
phic features. In addition, family history should be obtained to identify
the consanguineous relationships, other family cases with severe
obesity/bariatric surgery and the ethnic and geographical origin of the
family.
Abnormalities in the medical history and/or the physical exami-
nation may be a potential endocrine, genetic or hypothalamic obesity
disorders. Patients with severe early onset obesity (before 5 years
age), neurodevelopmental abnormalities and/or severe hyperphagia
are susceptible to the Mendelian form of obesity and genetic testing
should be performed. When these patients have a development delay,
karyotype and DNA methylation studies are a useful strategy for
identifying Prader‐Willi Syndrome. Patients with negative results and
additional features (retinal dystrophy, photophobia or nystagmus)
could indicate Bardet–Biedl syndrome, Alström syndrome or Tub
deﬁciency. However, patients with negative results and without these
additional features could be tested for Albright Hereditary Osteody-
strophy, BDNF, Trkb e SIM1 deﬁciency.
Additionally, severe obesity patients without development delays
should have leptin, proinsulin and insulin levels assessed. When these
subjects have decreased or undetectable leptin levels, it might indicate
LEP deﬁciency. Nevertheless, elevated ratio of proinsulin/insulin
(mature) levels suggest PCSK1 deﬁciency. Finally, patients with normal
levels of those hormones may be genetically tested to different
deﬁciencies, such as LEP, LEPR, POMC, MC4R, SH2B1 and KSR2.142,143
Importantly, consideration should be given to the ethical aspects of
genetic testing and its implications. Pretest counseling is warranted,
to establish realistic expectations for unveiling a causative gene
variant, and to make patients and families aware that a positive resultPlease cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017is unlikely to change the clinical management, given the lack of
available targeted therapies. Also, the discovery of incidental ﬁndings
unrelated to the reason for testing might create additional stress to
the patient, and should be clearly disclosed. Furthermore, the
implications of a positive ﬁnding to biological relatives should be
discussedwith the patient, as well as the fact that the interpretation of
a positive result should be correlated with clinical ﬁndings. Finally,
although genetic testing costs, particularly of NGS, are decreasing,
widespread use of these diagnostic tools still adds ﬁnancial burden to
patients and the healthcare system.
6. Current clinical approach in non-syndromic monogenic obesity
Promising approaches based on high-throughput next-generation
sequencing technologies have the potential to guide a robust genetic
diagnosis and identify new genes and pathways in the future.
Molecular diagnosis of monogenic obesity is important to the patients
and their families, since the clinicians could manage the patient
appropriately and provide the genetic counseling.143,144 The man-
agement of these patients based on lifestyle and behavioral
modiﬁcation appears to not be so efﬁcient long-term, since they are
relatively resistant to losing and/or maintaining the weight loss.142,145
Bariatric surgery is an effective therapy for severe obesity;
however, the efﬁcacy in patients with monogenic forms of obesity
has extremely limited data and is still up for debate.142,146 Adult
patients with heterozygous MC4R mutations who were submitted to
Roux-en-Y gastric bypass had an effect of excess weight loss
compared to a cohort of controls without MC4R mutations. Those
patients were able to lose about 60% of excess weight after the
surgery.147 In addition, four adolescents with heterozygous MC4R
mutations were evaluated in a restrictive bariatric surgery, in which
three underwent laparoscopic adjustable gastric banding and one was
submitted to vertical sleeve gastrectomy. The four patients and theirndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
LEP
LEPR
PCSK1
POMC
TUB
SH2B1
MC4R
MRP2
KSR2
SIM1
BDNF
NTRK2
LRP2
Site of Action Physiological Pathway
Hypothalamus
Hypothalamus
Hypothalamus
Hypothalamus
Leptin-melanocortin
Leptin-melanocortin
Leptin-melanocortin
Leptin-melanocortin
Hypothalamus? Leptin-melanocortin?
Hypothalamus Leptin-melanocortin
Hypothalamus Leptin-melanocortin
Hypothalamus
Raf-MEK-ERK
Leptin-melanocortin
Hypothalamus? Peripheral
FFA/glucose metabolism?
Hypothalamus Leptin-melanocortin
Hypothalamus Leptin-melanocortin
Hypothalamus Leptin-melanocortin
Hypothalamus Leptin-melanocortin
Fig. 3. Sites of involvement of the various genes associated with obesity and the
physiological pathways affected by them. Schematic representation of the sites of
action of the proteins expressed by the genes associated with obesity, and the pathways
affected by them. LEP: leptin; LEPR: leptin receptor; PCSK1: proprotein convertase
subtilisin/kexin type 1; POMC: pro-opiomelanocortin; TUB: tubby bipartite transcrip-
tion factor; SH2B1: Src homology 2 B adapter protein 1; MC4R: melanocortin-4
receptor; MRAP2: melanocortin 2 receptor accessory proteins 2; KSR2: kinase
suppressor of ras 2; SIM1: single-minded homolog 1; BDNF: brain-derived neuro-
trophic factor; NTRK2: neurotrophic tyrosine kinase receptor type 2; LRP2: low-density
lipoprotein receptor 2; FFA: free fatty acids.
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change and percentage of excess weight loss at 1 year, postbariatric
surgery.148 In contrast to the above ﬁndings, Aslan et al.147 have
reported an unsuccessful case of weight loss in an adolescent patient
(18.7-year old) who is compound heterozygous for two loss of
function MC4R mutations. Those ﬁndings suggest the complete
functional loss of MC4R may render the bariatric surgery an
ineffective procedure to lose weight in the long-term. Unexpectedly,
Bonnefond et al.149 found that patients carrying gain of functionMC4R
mutations had higher risk of reoperation. Therefore, more studies
about the effect of bariatric surgery in patients with MC4R mutations
are necessary.
Nowadays, speciﬁc treatment is available for patients with leptin
deﬁciency. In these cases, adults and children are treated with
subcutaneous injection of recombinant human leptin, reducing food
intake and weight. Furthermore, the administration of metreleptin
improves most of the metabolic and endocrine dysfunctions seen in
these patients.83,133,150 Unfortunately, leptin treatment is inefﬁcient
in LEPR-deﬁcient patients, since their receptors are non-functional.
Additionally, there is no speciﬁc treatment for other human cases of
non-syndromic monogenic obesity. The physiological systems that
control appetite and regulate body weight may harbour numerous
targets for anti-obesity drugs. Thus, researchers are developing new
molecules for pharmacological obesity treatment which act on the
leptin-melanocortin pathway; however it is still in clinical trials.151
7. Conclusion
Clearly, obesity is a complex disease inﬂuenced by different
factors. In most cases, the individual variability of becoming obese is
due to many gene variants of minor effect. However, several studies
have reported patients with severe early-onset obesity and endocrinePlease cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017dysfunctions caused by single gene mutations that disrupt the
development of the hypothalamus and leptin-melanocortin pathway
(Fig. 3). In the past few years, several molecular approaches and
technologies were developed and have provided a small understand-
ing of the genetic background of obesity. New genetic tools, such as
whole-genome/exome sequencing, have been identifying novel
variants and genes associated with common and rare forms of
obesity. Those high-throughput DNA sequencing technologies have
increasingly been used in the clinics, and their contribution to the
development of new therapeutic targets for Mendelian obesity, and to
the improvement quality of life remains to be determined.References
1. World Health Organization. Childhood overweight and obesity. Available at:
http://www.who.int/dietphysicalactivity/childhood/en/2015. [Accessed 11
March 2017].
2. Centers for Disease Control and Prevention. Youth risk behavior surveillance—-
United States, 2011. Available at:http://www.cdc.gov/mmwr/preview/
mmwrhtml/ss6104a1.htm2012. [Accessed 12 March 2017].
3. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult
obesity in the United States, 2011–2012. JAMA. 2014;311:806-14, http:
//dx.doi.org/10.1001/jama.2014.732.
4. Rosaneli CF, Baena CP, Auler F, Nakashima ATA, Netto-Oliveira ER, Oliveira AB,
et al. Elevated blood pressure and obesity in childhood: a cross-sectional
evaluation of 4,609 schoolchildren. Arq Bras Cardiol. 2014:238-44, http:
//dx.doi.org/10.5935/abc.20140104.
5. World Health Organization. Obesity and overweight. Available at:http://www.
who.int/mediacentre/factsheets/fs311/en/2016. [Accessed 21 December 2016].
6. World Health Organization. Global status report on noncommunicable diseases:
World Health Organization. Available at:http://apps.who.int/iris/bitstream/10665/
148114/1/9789241564854_eng.pdf?ua=12014. [Accessed 13 March 2017].
7. NgM, Fleming T, RobinsonM, Thomson B, Graetz N, Margono C, et al. Global, regional,
andnational prevalenceof overweight andobesity in children andadults during1980–
2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet.
2014;384:766-81, http://dx.doi.org/10.1016/S0140-6736(14)60460-8.
8. Wabitsch M, Moss A, Kromeyer-Hauschild K. Unexpected plateauing of childhood
obesity rates in developed countries. BMC Med. 2014;12:17, http:
//dx.doi.org/10.1186/1741-7015-12-17.
9. Whitaker RC, Wright JA, Pepe MS, Seidel KD, Dietz WH. Predicting obesity in
young adulthood from childhood and parental obesity. N Engl J Med. 1997;337:
869-73, http://dx.doi.org/10.1056/NEJM199709253371301.
10. Kumar S, Kelly AS. Review of childhood obesity. Mayo Clin Proc. 2017:1-15, http:
//dx.doi.org/10.1016/j.mayocp.2016.09.017.
11. Sahoo K, Sahoo B, Choudhury A, Suﬁ N, Kumar R, Bhadoria AS. Childhood obesity:
causes and consequences. J Fam Med Prim Care. 2015;4:187, http:
//dx.doi.org/10.4103/2249-4863.154628.
12. Sawyer MG, Harchak T, Wake M, Lynch J. Four-year prospective study of BMI and
mental health problems in young children. Pediatrics. 2011. [Retrieved from
http://pediatrics.aappublications.org/content/early/2011/09/15/peds.2010-
3132.abstract].
13. Strauss RS. Childhood obesity and self-esteem. Pediatrics. 2000;105:e15 LP-e15.
[Retrieved from http://pediatrics.aappublications.org/content/105/1/e15.
abstract].
14. Berkowitz RI, Daniels S. Now is the time to improve access and healthcare systems
for chi ldhood obesi ty treatment . Obesi ty . 2017;25:13-4, http:
//dx.doi.org/10.1002/oby.21740.
15. Orsi CM, Hale DE, Lynch JL. Pediatric obesity epidemiology. Curr Opin Endocrinol
Diabetes Obes. 2011;18. [Retrieved from http://journals.lww.com/co-
endocrinology/Fulltext/2011/02000/Pediatric_obesity_epidemiology.5.aspx].
16. Lynch BA, Finney Rutten LJ, Jacobson RM, Kumar S, Elrashidi MY, Wilson PM, et al.
Health care utilization by body mass index in a pediatric population. Acad Pediatr.
2015;15:644-50, http://dx.doi.org/10.1016/j.acap.2015.08.009.
17. Trasande L, Chatterjee S. The impact of obesity on health service utilization and costs
in childhood. Obesity. 2009;17:1749-54, http://dx.doi.org/10.1038/oby.2009.67.
18. Kasman M, Hammond RA, Werman A, Mack-Crane A, McKinnon RA. An in-depth
look at the lifetime economic cost of obesity. Brookings Institute. 2015.
19. Lakshman R, Elks CE, Ong KK. Childhood obesity. Circulation. 2012;126:1770-9.
[Retrieved from http://circ.ahajournals.org/content/126/14/1770.abstract].
20. Xia Q, Grant SF. The genetics of human obesity. Ann N Y Acad Sci. 2013;1281:
178-90, http://dx.doi.org/10.1111/nyas.12020.
21. Farooqi IS, O'Rahilly S. New advances in the genetics of early onset obesity. Int J
Obes (Lond). 2005;29:1149-52, http://dx.doi.org/10.1038/sj.ijo.0803056.
22. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of
body mass index yield new insights for obesity biology. Nature. 2015;518:
197-206, http://dx.doi.org/10.1038/nature14177.
23. O'Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature.
2009;462:307-14, http://dx.doi.org/10.1038/nature08532.
24. Paz-Filho G, Mastronardi C, Delibasi T, Wong M, Licinio J. Congenital leptin
deﬁciency: diagnosis and effects of leptin replacement therapy. Arq Bras Endocrinol
Metabol. 2010;54:690-7, http://dx.doi.org/10.1590/S0004-27302010000800005.ndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
11A.C.P. da Fonseca et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxx25. Montague CT, Farooqi IS, Wareham NJ, Sewter CP, Cheetham CH, Earley AR, et al.
Congenital leptin deﬁciency is associated with severe early-onset obesity in
humans. Nature. 1997;387:903-8, http://dx.doi.org/10.1038/43185.
26. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, et al. A mutation in
the human leptin receptor gene causes obesity and pituitary dysfunction. Nature.
1998;392:398-401.
27. Saeed S, Bonnefond A, Manzoor J, Philippe J, Durand E, ArshadM, et al. Novel LEPR
mutations in obese Pakistani children identiﬁed by PCR-based enrichment and
next generation sequencing. Obesity (Silver Spring). 2014;22:1112-7, http:
//dx.doi.org/10.1002/oby.20667.
28. Farooqi SI,Wangensteen T, Collins S, KimberW,Matarese G, Keogh JM, et al. Clinical
and molecular genetic spectrum of congenital deﬁciency of the leptin receptor. N
Engl J Med. 2007;356:237-47, http://dx.doi.org/10.1056/NEJMoa063988.Clinical.
29. Farooqi IS, Volders K, Stanhope R, Heuschkel R, White A, Lank E, et al.
Hyperphagia and early-onset obesity due to a novel homozygous missense
mutation in prohormone convertase 1/3. J Clin Endocrinol Metabol. 2007;92:
3369-73, http://dx.doi.org/10.1210/jc.2007-0687.
30. Kühnen P, Clement K,Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, et al.
Proopiomelanocortin deﬁciency treated with a melanocortin-4 receptor agonist.
N Engl J Med. 2016;375:240-6, http://dx.doi.org/10.1056/NEJMoa1512693.
31. Borman AD, Pearce LR, Mackay DS, Nagel-Wolfrum K, Davidson AE, Henderson R,
et al. A homozygousmutation in the TUB gene associatedwith retinal dystrophy and
obesity. Hum Mutat. 2014;35:289-93, http://dx.doi.org/10.1002/humu.22482.
32. Doche ME, Henning E, Cline JM, Dale A, Cheetham T, Argetsinger LS, et al. Human
SH2B1 mutations are associated with maladaptive behaviors and obesity. J Clin
Invest. 2012;122:4732-6, http://dx.doi.org/10.1172/JCI62696.4732.
33. Rui L. SH2B1 regulation of energy balance, body weight, and glucose metabolism.
World J Diabetes. 2014;5:511-26, http://dx.doi.org/10.4239/wjd.v5.i4.511.
34. Doulla M,McIntyre AD, Hegele RA, Gallego PH. A novel MC4Rmutation associated
with childhood-onset obesity: a case report. Paediatr Child Health. 2014;19:515-8.
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276379/].
35. Farooqi IS, Keogh JM, Yeo GSH, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum
of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med.
2003;348:1085-95, http://dx.doi.org/10.1056/NEJMoa022050.
36. Melchior C, Schulz A, Windholz J, Kiess W, Schneberg T, Krner A. Clinical and
functional relevance of melanocortin-4 receptor variants in obese german children.
Horm Res Paediatr. 2012;78:237-46, http://dx.doi.org/10.1159/000343816.
37. Farooqi SI. Genetic, molecular and physiological mechanisms involved in human
obesity: society for endocrinology medal lecture 2012. Clin Endocrinol (Oxf).
2015;82:23-8, http://dx.doi.org/10.1111/cen.12588.
38. Asai M, Ramachandrappa S, Joachim M, Shen Y, Zhang R, Nuthalapati N, et al. Loss of
functionof themelanocortin2receptoraccessoryprotein2 isassociatedwithmammalian
obesity. Science. 2013;341:275-8, http://dx.doi.org/10.1126/science.1233000.
39. Schonnop L, Kleinau G, Herrfurth N, Volckmar A-L, Cetindag C, Müller A, et al.
Decreased melanocortin-4 receptor function conferred by an infrequent variant
at the human melanocortin receptor accessory protein 2 gene. Obesity. 2016;24:
1976-82, http://dx.doi.org/10.1002/oby.21576.
40. Pearce LR, Atanassova N, BantonMC, Bottomley B, Van Der Klaauw AA, Revelli JP, et al.
KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular
fuel oxidation. Cell. 2013;155:765-77, http://dx.doi.org/10.1016/j.cell.2013.09.058.
41. Costanzo-GarveyDL,PﬂugerPT,DoughertyMK,Stock JL,BoehmM,ChaikaO,et al. KSR2
is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell
Metab. 2009;10:366-78, http://dx.doi.org/10.1016/j.cmet.2009.09.010.
42. Ramachandrappa S, Gorrigan RJ, Clark AJL, Chan LF. The melanocortin receptors
and their accessory proteins. Front Endocrinol. 2013;4:1-8, http:
//dx.doi.org/10.3389/fendo.2013.00009.
43. Holder JL, Zhang L, Kublaoui BM, DiLeone RJ, Oz OK, Bair CH, et al. Sim1 gene
dosage modulates the homeostatic feeding response to increased dietary fat in
mice . Am J Phys io l Endocr ino l Metab . 2004;287:E105-3 , http :
//dx.doi.org/10.1152/ajpendo.00446.2003.
44. Gray J, Yeo GSH, Cox JJ, Morton J, Adlam A-LR, Keogh JM, et al. Hyperphagia, severe
obesity, impaired cognitive function, and hyperactivity associated with functional
loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes.
2006;55:3366-71, http://dx.doi.org/10.2337/db06-0550.
45. Yeo GSH, Connie Hung C-C, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, et al. A de
novomutation affecting human TrkB associatedwith severe obesity and developmen-
tal delay. Nat Neurosci. 2004;7:1187-9, http://dx.doi.org/10.1038/nn1336.
46. Paz-Filho G, Boguszewski MCS, Mastronardi CA, Patel HR, Johar AS, Chuah A, et al.
Whole exome sequencing of extreme morbid obesity patients: translational
implications for obesity and related disorders. Genes. 2014;5:709-25, http:
//dx.doi.org/10.3390/genes5030709.
47. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity
among children in the United States, 1999–2012. JAMA Pediatr. 2014;168:561-6,
http://dx.doi.org/10.1001/jamapediatrics.2014.21.
48. Garnett SP, Baur LA, Jones AMD, Hardy LL. Trends in the prevalence of morbid and
severe obesity in Australian children aged 7–15 years, 1985–2012. PloS One.
2016;11:e0154879, http://dx.doi.org/10.1371/journal.pone.0154879.
49. Sandholt CH, Grarup N, Pedersen O, Hansen T. Genome-wide association studies
of human adiposity: zooming in on synapses. Mol Cell Endocrinol. 2015;418:
90-100, http://dx.doi.org/10.1016/j.mce.2015.09.029.
50. Yazdi FT, Clee SM, Meyre D. Obesity genetics in mouse and human: back and
forth, and back again. PeerJ. 2015;3:e856, http://dx.doi.org/10.7717/peerj.856.
51. van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. Cell.
2015;161:119-32, http://dx.doi.org/10.1016/j.cell.2015.03.008.
52. Walley AJ, Asher JE, Froguel P. The genetic contribution to non-syndromic human
obesity. Nat Rev Genet. 2009;10:431-42, http://dx.doi.org/10.1038/nrg2594.Please cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (201753. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, et al.
Association analyses of 249,796 individuals reveal 18 new loci associated with
body mass index. Nat Genet. 2010;42:937-48, http://dx.doi.org/10.1038/ng.686.
54. McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, et al. Ten
putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49:
868-913, http://dx.doi.org/10.1080/10408390903372599.
55. Yang W, Kelly T, He J. Genetic epidemiology of obesity. Epidemiol Rev. 2007;29:
49-61, http://dx.doi.org/10.1093/epirev/mxm004.
56. Bouchard C, Tremblay A, Després J-P, Nadeau A, Lupien PJ, Thériault G, et al. The
response to long-term overfeeding in identical twins. N Engl J Med. 1990;322:
1477-82, http://dx.doi.org/10.1056/NEJM199005243222101.
57. Bouchard C, Tremblay A, Després J-P, Thériault G, Nadeauf A, Lupien PJ, et al. The
response to exercise with constant energy intake in identical twins. Obes Res.
1994;2:400-10, http://dx.doi.org/10.1002/j.1550-8528.1994.tb00087.x.
58. Stunkard AJ, Sørensen TIA, Hanis C, Teasdale TW, Chakraborty R, Schull WJ, et al.
An adoption study of human obesity. N Engl J Med. 1986;314:193-8, http:
//dx.doi.org/10.1056/NEJM198601233140401.
59. Huvenne H, Dubern B, Clément K, Poitou C. Rare genetic forms of obesity: clinical
approach and current treatments in 2016. Obes Facts. 2016;9:158-73, http:
//dx.doi.org/10.1159/000445061.
60. Albuquerque D, Stice E, Rodríguez-López R, Manco L, Nóbrega C. Current review of
geneticsofhumanobesity: frommolecularmechanismstoanevolutionaryperspective.
Mol Genet Genomics. 2015;290:1991, http://dx.doi.org/10.1007/s00438-015-1015-9.
61. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet.
2005;6:221-34, http://dx.doi.org/10.1038/nrg1556.
62. Larder R, Lim CT, Coll AP. Chapter 6 - genetic aspects of human obesity. In: Fliers Eric,
Korbonits Márta, Romijn Johannes A, eds. Clinical neuroendocrinology, Vol. 124.
Elsevier; 2014. p. 93-106, http://dx.doi.org/10.1016/B978-0-444-59602-4.00006-X.
63. Anand BK, Brobeck JR. Hypothalamic control of food intake in rats and cats. Yale J
Biol Med. 1951;24:123-40. [Retrieved from http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC2599116/].
64. Hetherington AW, Ranson SW. Hypothalamic lesions and adiposity in the rat.
Anat Rec. 1940;78:149-72, http://dx.doi.org/10.1002/ar.1090780203.
65. Daousi C, Dunn AJ, Foy PM, MacFarlane IA, Pinkney JH. Endocrine and
neuroanatomic features associated with weight gain and obesity in adult patients
with hypothalamic damage. Am J Med. 2005;118:45-50, http:
//dx.doi.org/10.1016/j.amjmed.2004.06.035.
66. VetterML,FaulconbridgeLF,WebbVL,WaddenTa.Behavioralandpharmacologictherapies
for obesity.Nat Rev Endocrinol. 2010;6:578-88, http://dx.doi.org/10.1038/nrendo.2010.121.
67. Ranadive SA, Vaisse C. Lessons from extreme human obesity: monogenic
disorders. Endocrinol Metab Clin North Am. 2008;37:733-51, http:
//dx.doi.org/10.1016/j.ecl.2008.07.003.
68. Romieu I, Dossus L, Barquera S, Blottière HM, Franks PW, Gunter M, et al. Energy
balance and obesity: what are the main drivers? Cancer Causes Control. 2017;28:
247-58, http://dx.doi.org/10.1007/s10552-017-0869-z.
69. Smith AI, Funder JW. Proopiomelanocortin processing in the pituitary, central
nervous system, and peripheral tissues. Endocr Rev. 1988;9:159-79, http:
//dx.doi.org/10.1210/edrv-9-1-159.
70. Tao Y-X. Molecular mechanisms of the neural melanocortin receptor dysfunction
in severe early onset obesity. Mol Cell Endocrinol. 2005;239:1-14, http:
//dx.doi.org/10.1016/j.mce.2005.04.012.
71. Cone RD. Anatomy and regulation of the central melanocortin system. Nat
Neurosci. 2005;8:571-8. [Retrieved from http://dx.doi.org/10.1038/nn1455].
72. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous
system control of food intake and body weight. Nature. 2006;443:289-95.
[Retrieved from http://dx.doi.org/10.1038/nature05026].
73. Sutton AK, Myers MG, Olson DP. The role of PVH circuits in leptin action and
en e r g y b a l a n c e . Annu R e v P h y s i o l . 2 016 ; 7 8 : 2 07 - 2 1 , h t t p :
//dx.doi.org/10.1146/annurev-physiol-021115-105347.
74. Chesi A, Grant SFA. The genetics of pediatric obesity. Trends Endocrinol Metab.
2015;26:711-21, http://dx.doi.org/10.1016/j.tem.2015.08.008.
75. Savona-Ventura C, Savona-Ventura S. The inheritance of obesity. Best Pract Res Clin
Obstet Gynaecol. 2015;29:300-8, http://dx.doi.org/10.1016/j.bpobgyn.2014.07.023.
76. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J
Hered. 1950;41:315-7, http://dx.doi.org/10.1093/oxfordjournals.jhered.a106072.
77. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice.
Diabetologia. 1973;9:294-8, http://dx.doi.org/10.1007/BF01221857.
78. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional
cloning of the mouse obese gene and its human homologue. Nature. 1994, http:
//dx.doi.org/10.1038/372425a0.
79. Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, et al.
Congenital leptin deﬁciency due to homozygosity for the Δ133Gmutation: report
of another case and evaluation of response to four years of leptin therapy. J Clin
Endocrinol Metabol. 2004;89:4821-6, http://dx.doi.org/10.1210/jc.2004-0376.
80. Saeed S, Bonnefond A, Manzoor J, Shabir F, Ayesha H, Philippe J, et al. Genetic
variants in LEP, LEPR, and MC4R explain 30% of severe obesity in children from a
consanguineous population. Obesity (Silver Spring). 2015;23:1687-95, http:
//dx.doi.org/10.1002/oby.21142.
81. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations.
Metabolism. 2015;64:146-56, http://dx.doi.org/10.1016/j.metabol.2014.07.014.
82. Paz-Filho G,WongML, Licinio J. Ten years of leptin replacement therapy. Obes Rev.
2011;12:315-23, http://dx.doi.org/10.1111/j.1467-789X.2010.00840.x.
83. Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, et al.
Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus,
hypogonadism, and behavior in leptin-deﬁcient adults. Proc Natl Acad Sci.
2004;101:4531-6, http://dx.doi.org/10.1073/pnas.0308767101.ndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
12 A.C.P. da Fonseca et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxx84. Wabitsch M, Funcke J-B, Lennerz B, Kuhnle-Krahl U, Lahr G, Debatin K-M, et al.
Biologically inactive leptin and early-onset extreme obesity. N Engl J Med.
2015;372:48-54, http://dx.doi.org/10.1056/NEJMoa1406653.
85. Gill R, Cheung YH, Shen Y, Lanzano P,Mirza NM, Ten S, et al.Whole-exome sequencing
identiﬁes novel LEPR mutations in individuals with severe early onset obesity. Obesity
(Silver Spring). 2014;22:576-84, http://dx.doi.org/10.1002/oby.20492.
86. Clark AJL. 60 YEARS OF POMC: the proopiomelanocortin gene: discovery, deletion and
disease. J Mol Endocrinol. 2016;56:T27-37, http://dx.doi.org/10.1530/JME-15-0268.
87. Clément K, Dubern B, Mencarelli M, Czernichow P, Ito S, Wakamatsu K, et al.
Unexpected endocrine features and normal pigmentation in a young adult patient
carrying a novel homozygous mutation in the POMC gene. J Clin Endocrinol
Metabol. 2008;93:4955-62, http://dx.doi.org/10.1210/jc.2008-1164.
88. Krude H, Biebermann H, LuckW, Horn R, Brabant G, Grüters A. Severe early-onset
obesity, adrenal insufﬁciency and red hair pigmentation caused by POMC
mutations in humans. Nat Genet. 1998;19:155-7, http://dx.doi.org/10.1038/509.
89. Farooqi IS, Drop S, Clements A, Keogh JM, Biernacka J, Lowenbein S, et al.
Heterozygosity for a POMC-null mutation and increased obesity risk in humans.
Diabetes. 2006;55:2549-53, http://dx.doi.org/10.2337/db06-0214.
90. Mendiratta MS, Yang Y, Balazs AE, Willis AS, Eng CM, Karaviti LP, et al. Early onset
obesity and adrenal insufﬁciency associatedwith a homozygous POMCmutation. Int
J Pediatr Endocrinol. 2011;2011:5, http://dx.doi.org/10.1186/1687-9856-2011-5.
91. Samuels ME, Gallo-Payet N, Pinard S, Hasselmann C, Magne F, Patry L, et al.
Bioinactive ACTH causing glucocorticoid deﬁciency. J Clin Endocrinol Metabol.
2013;98:736-42, http://dx.doi.org/10.1210/jc.2012-3199.
92. Müller TD, Tschöp MH, O'Rahilly S. Metabolic precision medicines: curing POMC
deﬁciency. Cell Metab. 2016;24:194-5, http://dx.doi.org/10.1016/j.cmet.2016.07.006.
93. Frank GR, Fox J, Candela N, Jovanovic Z, Bochukova E, Levine J, et al. Severe obesity
and diabetes insipidus in a patient with PCSK1 deﬁciency. Mol Genet Metab.
2013;110:191-4, http://dx.doi.org/10.1016/j.ymgme.2013.04.005.
94. HoshinoA, Lindberg I. Peptidebiosynthesis: prohormoneconvertases 1/3and2.ColloqSer
Neuropeptides. 2012;1:1-112, http://dx.doi.org/10.4199/C00050ED1V01Y201112NPE001.
95. ValetteM,Bellisle F, Carette C, PoitouC,DubernB, ParadisG, et al. Eatingbehaviour in
obese patients with melanocortin-4 receptor mutations: a literature review. Int J
Obes (Lond). 2013;37:1027-35, http://dx.doi.org/10.1038/ijo.2012.169.
96. Jackson RS, Creemers JWM, Farooqi IS, Rafﬁn-Sanson ML, Varro A, Dockray GJ,
et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of
human proprotein convertase 1 deﬁciency. J Clin Investig. 2003;112:1550-60,
http://dx.doi.org/10.1172/JCI200318784.
97. Jackson RS, Creemers JWM, Ohagi S, Rafﬁn-Sanson ML, Sanders L, Montague CT,
et al. Obesity and impaired prohormone processing associated with mutations in
the humam prohormone convertase 1 gene. Nat Genet. 1997;16:303-6.
98. Martín MG, Solorzano-Vargas RS, Wang J, Avitzur Y, Bandsma R, Sokollik C, et al.
Congenital proprotein convertase 1/3 deﬁeciency causes malabsortive diarrhea
and other endocrinopathies in a pediatric cohort. Gastroenterology. 2013;145:
138-48, http://dx.doi.org/10.1016/j.freeradbiomed.2008.10.025.The.
99. Philippe J, Stijnen P,Meyre D,DeGraeve F, ThuillierD, Delplanque J, et al. A nonsense
loss-of-function mutation in PCSK1 contributes to dominantly inherited human
obesity. Int J Obes (Lond). 2015;39:1-30, http://dx.doi.org/10.1038/ijo.2014.96.
100. Kleyn PW, Fan W, Kovats SG, Lee JJ, Pulido JC, Wu Y, et al. Identiﬁcation and
characterization of the mouse obesity gene tubby: a member of a novel gene
family. Cell. 1996;85:281-90, http://dx.doi.org/10.1016/S0092-8674(00)81104-6.
101. Prada PO, Quaresma PGF, Caricilli AM, Santos AC, Guadagnini D, Morari J, et al. Tub
has a key role in insulin and leptin signaling and action in vivo in hypothalamic
nuclei. Diabetes. 2013;62:137-48, http://dx.doi.org/10.2337/db11-1388.
102. Tapia-Arancibia L, Rage F, Givalois L, Arancibia S. Physiology of BDNF: focus on
hypothalamic function. Front Neuroendocrinol. 2004;25:77-107, http:
//dx.doi.org/10.1016/j.yfrne.2004.04.001.
103. Gray J, YeoG,HungC,Keogh J, ClaytonP, BanerjeeK, et al. Functional characterization
of humanNTRK2mutations identiﬁed inpatientswith severe early-onset obesity. Int
J Obes (Lond). 2007;31:359-64, http://dx.doi.org/10.1038/sj.ijo.0803390.
104. Holder JL, Butte NF, Zinn AR. Profound obesity associatedwith a balanced translocation
thatdisrupts theSIM1gene.HumMolGenet.2000;9:101-8. [https://doi.org/ddd012pii].
105. Ramachandrappa S, Raimondo A, Cali AMG, Keogh JM, Henning E, Saeed S, et al.
Rare variants in single-minded 1 (SIM1) are associated with severe obesity. J Clin
Investig. 2013;123:1-9, http://dx.doi.org/10.1172/JCI68016DS1.
106. Zegers D, Beckers S, Hendrickx R, Van Camp JK, de Craemer V, Verrijken A, et al.
Mutation screen of the SIM1 gene in pediatric patients with early-onset obesity.
Int J Obes (Lond). 2014;38:1000-4, http://dx.doi.org/10.1038/ijo.2013.188.
107. Dores RM, Liang L, Davis P, Thomas AL, Petko B. Melanocortin receptors: evolution
of ligand selectivity for melanocortin peptides. J Mol Endocrinol. 2016;56:T119-33,
http://dx.doi.org/10.1530/JME-15-0292.
108. Stanikova D, Surova M, Ticha L, Petrasova M, Virgova D, Huckova M, et al.
Melanocortin-4 receptor gene mutations in obese slovak children. Physiol Res.
2015;64:883-90, http://dx.doi.org/10.1073/pnas.0703993104.
109. Dubern B, Clément K, Pelloux V, Froguel P, Girardet JP, Guy-Grand B, et al.
Mutational analysis of melanocortin-4 receptor, agouti-related protein, and
alpha-melanocyte-stimulating hormone genes in severely obese children. J
Pediatr. 2001;139:204-9, http://dx.doi.org/10.1067/mpd.2001.116284.
110. Miraglia Del Giudice E, Cirillo G, Nigro V, Santoro N, D'Urso L, Raimondo P, et al.
Low frequency of melanocortin-4 receptor (MC4R) mutations in a Mediterranean
population with early-onset obesity. Int J Obes Relat Metab Disord. 2002;26:
647-51, http://dx.doi.org/10.1038/sj.ijo.0801983.
111. Polverelli M, Teoule R. Gamma irradiation of cytosine in an aerated aqueous
solution. II. Kinetic study of the formation of the radiolysis products of cytosine
resulting from the deamination pathway. Z Naturforsch C. 2014;29:16-8.
[Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4276379].Please cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017112. XiB,ChandakGR,ShenY,WangQ,ZhouD.Associationbetweencommonpolymorphism
near the MC4R gene and obesity risk: a systematic review andmeta-analysis. PLoS One.
2012;7:e45731, http://dx.doi.org/10.1371/journal.pone.0045731.
113. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, et al. Dominant and
recessive inheritance of morbid obesity associated with melanocortin 4 receptor
deﬁciency. J Clin Invest. 2000;106:271-9, http://dx.doi.org/10.1172/JCI9397.
114. Vollbach H, Brandt S, Lahr G, Denzer C, Von Schnurbein J, Debatin K-M, et al.
Prevalence and phenotypic characterization of MC4R variants in a large pediatric
cohort. International Journal of Obesity. Nature Publishing Group; 2016, http:
//dx.doi.org/10.1038/ijo.2016.161.
115. Chen KY, Muniyappa R, Abel BS, Mullins KP, Staker P, Brychta RJ, et al. RM-493, a
melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in
obese individuals. J Clin Endocrinol Metab. 2015;100:1639-45, http:
//dx.doi.org/10.1210/jc.2014-4024.
116. René P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, et al.
Pharmacological chaperones restore function to MC4R mutants responsible for
severe early-onset obesity. J Pharmacol Exp Ther. 2010;335:520-32, http:
//dx.doi.org/10.1124/jpet.110.172098.
117. Chan LF, Webb TR, Chung T-T, Meimaridou E, Cooray SN, Guasti L, et al. MRAP and
MRAP2 are bidirectional regulators of the melanocortin receptor family. Proc Natl
Acad Sci U S A. 2009;106:6146-51, http://dx.doi.org/10.1073/pnas.0809918106.
118. PearceLR, JoeR,DocheME, SuHW,Keogh JM,HenningE, et al. Functional characterization
of obesity-associated variants involving the α and β isoforms of human SH2B1.
Endocrinology. 2014;155:3219-26, http://dx.doi.org/10.1210/en.2014-1264.
119. Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, et al. Large,
rare chromosomal deletions associated with severe early-onset obesity. Nature.
2010;463:666-70, http://dx.doi.org/10.1038/nature08689.
120. Revelli J-P, Smith D, Allen J, Jeter-Jones S, Shadoan MK, Desai U, et al. Profound
obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2.
Obesity (Silver Spring). 2011;19:1010-8, http://dx.doi.org/10.1038/oby.2010.282.
121. Bowden DW, Sale M, Howard TD, Qadri A, Spray BJ, Rothschild CB, et al. Linkage of
genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib
pairs with a history of diabetic nephropathy. Diabetes. 1997;46:882-6, http:
//dx.doi.org/10.2337/diab.46.5.882.
122. LiWD,DongC, LiD, ZhaoH, Price RA. Anobesity-related locus in chromosome region
12q23-24. Diabetes. 2004;53:812-20, http://dx.doi.org/10.2337/diabetes.53.3.812.
123. Gil SY, Youn B-S, Byun K, Huang H, Namkoong C, Jang P, et al. Clusterin and LRP2
are critical components of the hypothalamic feeding regulatory pathway. Nat
Commun. 2013;4:1862-9, http://dx.doi.org/10.1038/ncomms2896.
124. Hu H, Roach JC, Coon H, Guthery SL, Voelkerding KV, Margraf RL, et al. A uniﬁed
test of linkage analysis and rare-variant association for analysis of pedigree
sequence data. Nat Biotechnol. 2014;32:663-9. [Retrieved from http://dx.doi.org/
10.1038/nbt.2895].
125. El-Sayed Moustafa JS, Froguel P. From obesity genetics to the future of
personalized obesity therapy. Nat Rev Endocrinol. 2013;9:402-13, http:
//dx.doi.org/10.1038/nrendo.2013.57.
126. Shashi V, McConkie-Rosell A, Rosell B, Schoch K, Vellore K, McDonald M, et al. The
utility of the traditional medical genetics diagnostic evaluation in the context of
next-generation sequencing for undiagnosed genetic disorders. Genet Med.
2014;16:176-82, http://dx.doi.org/10.1038/gim.2013.99.
127. Wheeler E, Huang N, Bochukova E, Keogh JM, Lindsay S, Garg S, et al.
Genome-wide SNP and CNV analysis identiﬁes common and low-frequency
variants associated with severe early-onset obesity. Nat Genet. 2012;100:130-4,
http://dx.doi.org/10.1016/j.pestbp.2011.02.012.Investigations.
128. Hasstedt SJ, Xin Y, Mao R, Lewis T, Adams TD, Hunt SC. A copy number variant on
chromosome 20q13.3 implicated in thinness and severe obesity. J Obes.
2015;2015:1-7, http://dx.doi.org/10.1155/2015/623431.
129. Dina C, Meyre D, Gallina S, Durand E, Körner A, Jacobson P, et al. Variation in FTO
contributes to childhood obesity and severe adult obesity. Nat Genet. 2007;39:
724-6, http://dx.doi.org/10.1038/ng2048.
130. Grant SF, Li M, Bradﬁeld JP, KimCE, Annaiah K, Santa E, et al. Association analysis of the
FTO genewith obesity in children of Caucasian and African ancestry reveals a common
tagging SNP. PLoSOne. 2008;3:e1746, http://dx.doi.org/10.1371/journal.pone.0001746.
131. Scuteri A, SannaS, ChenW-M,UdaM,AlbaiG, Strait J, et al. Genome-wide association
scan shows genetic variants in the FTO gene are associated with obesity-related
traits. PLoS Genet. 2007;3:e115, http://dx.doi.org/10.1371/journal.pgen.0030115.
132. Need AC, Shashi V, Hitomi Y, Schoch K, Shianna KV, McDonald MT, et al. Clinical
application of exome sequencing in undiagnosed genetic conditions. J Med Genet.
2012;49:353-61, http://dx.doi.org/10.1136/jmedgenet-2012-100819.
133. Farooqi IS, Jebb SA, LangmackG, Lawrence E, CheethamCH, PrenticeAM, et al. Effects
of recombinant leptin therapy in a child with congenital leptin deﬁciency. N Engl J
Med. 1999;341:879-84, http://dx.doi.org/10.1056/NEJM199909163411204.
134. Johar AS, Mastronardi C, Rojas-Villarraga A, Patel HR, Chuah A, Peng K, et al. Novel and
rare functional genomic variants in multiple autoimmune syndrome and Sjögren's
syndrome. J Transl Med. 2015;13:173, http://dx.doi.org/10.1186/s12967-015-0525-x.
135. Vélez JI, Lopera F, Patel HR, Johar AS, Cai Y, Rivera D, et al. Mutations modifying
sporadic Alzheimer's disease age of onset. Am J Med Genet B Neuropsychiatr Genet.
2016;171:1116-30, http://dx.doi.org/10.1002/ajmg.b.32493.
136. Ott J, Wang J, Leal SM. Genetic linkage analysis in the age of whole-genome
sequencing. Nat Rev Genet. 2015;16:275-84, http://dx.doi.org/10.1038/nrg3908.
137. Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, Van Kogelenberg M,
et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable
analysis of genome-wide research data. Lancet. 2015;385:1305-14, http:
//dx.doi.org/10.1016/S0140-6736(14)61705-0.
138. Posey JE, Rosenfeld JA, James RA, Bainbridge M, Niu Z, Wang X, et al. Molecular
diagnostic experience of whole-exome sequencing in adult patients. Genet Med.ndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
13A.C.P. da Fonseca et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxx2016. [American College of Medical Genetics and Genomics. Retrieved from
http://dx.doi.org/10.1038/gim.2015.142].
139. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM, Willemsen
MH, et al. Genome sequencing identiﬁes major causes of severe intellectual
disability. Nature. 2014;511:344-7. [Retrieved from http://dx.doi.org/10.1038/
nature13394].
140. Liu DJ, Leal SM. A novel adaptive method for the analysis of next-generation
sequencing data to detect complex trait associations with rare variants due to
gene main effects and interactions. PLoS Genet. 2010;6:e1001156. [Retrieved from
http://dx.doi.org/10.1371%2Fjournal.pgen.1001156].
141. Farooqi IS, O'Rahilly S. Mutations in ligands and receptors of the leptin-melano-
cortin pathway that lead to obesity. Nat Clin Pract Endocrinol Metab. 2008;4:
569-77. [Retrieved from http://dx.doi.org/10.1038/ncpendmet0966].
142. Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al.
Pediatric obesity—assessment, treatment, and prevention: an endocrine society
clinical practice guideline. J Clin Endocrinol Metabol. 2017;102:709-57.
143. Farooqi IS, O'Rahilly S. Genetic obesity syndromes. In: Grant SFA, ed. The genetics
of obesity. New York, NY: Springer New York; 2014. p. 23-32, http:
//dx.doi.org/10.1007/978-1-4614-8642-8_2.
144. Philippe J, Derhourhi M, Durand E, Vaillant E, Dechaume A, Rabearivelo I, et al.
What is the best NGS enrichment method for the molecular diagnosis of
monogenic diabetes and obesity? PLoS One. 2015;10:e0143373, http:
//dx.doi.org/10.1371/journal.pone.0143373.Please cite this article as: da Fonseca ACP, et al. Genetics of non-sy
sequencing technologies. Journal of Diabetes and Its Complications (2017145. Reinehr T, Hebebrand J, Friedel S, Toschke AM, Brumm H, Biebermann H, et al.
Lifestyle intervention in obese children with variations in the melanocortin 4
receptor gene. Obesity. 2009;17:382-9, http://dx.doi.org/10.1038/oby.2008.422.
146. Steffen R, Potoczna N, Bieri N, Horber FF. Successful multi-intervention treatment
of severe obesity: a 7-year prospective study with 96% follow-up. Obes Surg.
2009;19:3-12, http://dx.doi.org/10.1007/s11695-008-9675-8.
147. Aslan IR, Campos GM, CaltonMA, Evans DS,MerrimanRB, Vaisse C.Weight loss after
Roux-en-Y gastric bypass in obese patients heterozygous for MC4Rmutations. Obes
Surg. 2011;21:930-4, http://dx.doi.org/10.1007/s11695-010-0295-8.
148. Censani M, Conroy R, Deng L, Oberﬁeld SE, McMahon DJ, Zitsman JL, et al. Weight
loss after bariatric surgery in morbidly obese adolescents with MC4R mutations.
Obesity. 2014;22:225-31, http://dx.doi.org/10.1002/oby.20511.
149. Bonnefond A, Keller R, Meyre D, Stutzmann F, Thuillier D, Stefanov DG, et al.
Eating behavior, low-frequency functional mutations in the melanocortin-4
receptor (MC4R) gene, and outcomes of bariatric operations: a 6-year prospective
study. Diabetes Care. 2016;39:1384-92, http://dx.doi.org/10.2337/dc16-0115.
150. Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, et al. Beneﬁcial
effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/me-
tabolic dysfunction of human congenital leptin deﬁciency. J Clin Invest. 2002;110:
1093-103, http://dx.doi.org/10.1172/JCI15693.
151. Boughton CK, Murphy KG. Can neuropeptides treat obesity? A review of
neuropeptides and their potential role in the treatment of obesity. Br J Pharmacol.
2013;170:1333-48, http://dx.doi.org/10.1111/bph.12037.ndromic childhood obesity and the use of high-throughput DNA
), http://dx.doi.org/10.1016/j.jdiacomp.2017.04.026
